HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, March 29, 2019 (HealthDay News) -- Based on active surveillance data of acute respiratory illness (ARI), enterovirus D68 (EV-D68) was detected in 0.8 percent of patients in 2017 and in 13.9 percent in 2018, according to research published in the March 29 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Stephanie A. Kujawski, Ph.D., from the CDC in Atlanta, and colleagues detailed a preliminary characterization of EV-D68 testing and detections among emergency department and hospitalized patients with ARI during July 1 to Oct. 31, 2017, and during the same period in 2018 at seven New Vaccine Surveillance Network sites.
The researchers detected EV-D68 in two patients (0.8 percent) in 2017 and in 358 patients (13.9 percent) in 2018. In 2017, one patient was hospitalized and one was evaluated in the emergency department; the patients were at two different sites. In 2018, 67.6 percent of patients were hospitalized; patients were identified at all seven sites. Of the 2018 EV-D68 detections, 47.2 percent occurred in September; the peak of detections varied by site.
"Continued surveillance for EV-D68-associated ARI is needed to better understand the epidemiology of EV-D68 in the United States," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 27, 2022